You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.201.0.0/16 has been blocked (disabled) by ‪ST47‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider. To prevent abuse, web hosts may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a web host's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and they should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 23:54, 31 July 2024.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:55, 18 August 2022
- Expiry of block: 13:55, 18 April 2025
Your current IP address is 44.201.28.123. The blocked range is 44.201.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((short description|Medical analysis of disease))
((Multiple issues|
((more citations needed|date=May 2014))
((Expert needed|Medicine|documentation|talk=Dubious current content|reason=tone and sophistication of existing content are non-encyclopedic, and alongside complete lack of citations (disallowing content verification), article is untrustworthy apart from expert attention|date=May 2014))
((Disputed|Dubious current content|date=May 2014)). 
))

'''Survival rate''' is a part of [[survival analysis]]. It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing [[prognosis]] in certain disease conditions, and can be used for the assessment of standards of therapy. The survival period is usually reckoned from date of diagnosis or start of treatment. Survival rates are based on the population as a whole and cannot be applied directly to an individual.<ref>((Cite web|url=http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44301|title=NCI Dictionary of Cancer Terms|website=National Cancer Institute|access-date=2016-04-22|date=2011-02-02))</ref> There are various types of survival rates (discussed below). They often serve as [[end point of clinical trials|endpoints of clinical trials]] and should not be confused with [[mortality rates]], a population metric.

==Overall survival==
[[Patient]]s with a certain [[disease]] (for example, [[colorectal cancer]]) can die directly from that disease or from an unrelated cause (for example, a [[car accident]]). When the precise [[cause of death]] is not specified, this is called the '''overall survival rate''' or '''observed survival rate'''. Doctors often use mean overall survival rates to estimate the patient's prognosis. This is often expressed over standard time periods, like one, five, and ten years. For example, [[prostate cancer]] has a much higher one-year overall survival rate than [[pancreatic cancer]], and thus has a better prognosis.

Sometimes the overall survival is reported as a death rate (%) without specifying the period the % applies to (possibly one year) or the period it is averaged over (possibly five years), e.g. [https://www.ncbi.nlm.nih.gov/pubmed/26705497 ''Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia''].

==Net survival rate==
When someone is interested in how survival is affected by the disease, there is also the '''net survival rate''', which filters out the effect of mortality from other causes than the disease. The two main ways to calculate net survival are '''[[relative survival]]''' and '''cause-specific survival''' or '''disease-specific survival'''.

Relative survival has the advantage that it does not depend on accuracy of the reported cause of death; cause specific survival has the advantage that it does not depend on the ability to find a similar population of people without the disease.

===Relative survival===
((Main|Relative survival))
[[Relative survival]] is calculated by dividing the overall survival after diagnosis of a disease by the survival as observed in a similar population that was not diagnosed with that disease.<ref>((cite journal | vauthors = Mariotto AB, Noone AM, Howlader N | title = Cancer Survival: An Overview of Measures, Uses, and Interpretation | journal = JNCI Monographs | date=November 2014 | volume = 2014 | issue = 49 | pages = 145–186 | doi=10.1093/jncimonographs/lgu024 | pmid = 25417231| pmc = 4829054 | doi-access = free ))</ref> A similar population is composed of individuals with at least age and gender similar to those diagnosed with the disease.

===Cause-specific survival and disease-specific survival===
Disease-specific survival rate refers to "the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time. The time period usually begins at the time of diagnosis or at the start of treatment and ends at the time of death. Patients who died from causes other than the disease being studied are not counted in this measurement."<ref>[http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44311 Definition : disease-specific survival rate]</ref>

==Median survival==
[[Median]] survival, or "median overall survival" is also commonly used to express survival rates. This is the amount of time after which 50% of the patients have died and 50% have survived. In ongoing settings such as [[clinical trial]]s, the median has the advantage that it can be calculated once 50% of subjects have reached the [[clinical endpoint]] of the trial, whereas calculation of an [[arithmetical mean]] can only be done after all subjects have reached the endpoint.<ref>((cite web|title=median overall survival|url=http://www.cancer.gov/dictionary?cdrid=655248|website=NCI Dictionary of Cancer Terms|publisher=National Cancere Institute|access-date=4 December 2014|date=2011-02-02))</ref>

The median overall survival is frequently used by the U.S. [[Food and Drug Administration]] to evaluate the effectiveness of a novel cancer treatment. Studies find that new cancer drugs approved by the U.S. [[Food and Drug Administration]] improve overall survival by a median of 2 to 3 months depending on the sample and analyzed time period: 2.1 months,<ref name="Fojo et al. (2014)">((cite journal  |vauthors=Fojo T, Mailankody S, Lo A |title=Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture |journal=JAMA Otolaryngol Head Neck Surg |volume=140 |issue=12 |pages=1225–1236 |year=2014 |pmid=25068501|doi=10.1001/jamaoto.2014.1570))</ref> 2.4 months,<ref name="Ladanie et al. (2020)">((cite journal  |vauthors=Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JP, Bucher HC, Kasenda B, Hemkens LG |title=Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016 |journal=JAMA Netw Open |volume=3 |issue=11 |pages=e2024406 |year=2020 |pmid=33170262|doi=10.1001/jamanetworkopen.2020.24406|pmc=7656288 ))</ref> 2.8 months.<ref name="Michaeli & Michaeli (2020)">((cite journal  |vauthors=Michaeli DT, Michaeli T |title=Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021 |journal=Journal of Clinical Oncology | year=2022 |volume=40 |issue=35 |pages=4095–4106 |pmid=35921606|doi=10.1200/JCO.22.00535|s2cid=251317641 ))</ref>

==Five-year survival==
((Main|Five-year survival rate))
[[Five-year survival rate]] measures survival at five years after diagnosis.

==Disease-free survival, progression-free survival, and metastasis-free survival==
((Main|Progression-free survival))
In [[cancer research]], various types of survival rate can be relevant, depending on the [[cancer]] type and [[cancer staging|stage]]. These include the '''disease-free survival''' (DFS) (the period after curative treatment [disease eliminated] when no disease can be detected), the [[progression-free survival]] (PFS) (the period after treatment when disease [which could not be eliminated] remains stable, that is, does not progress), and the '''metastasis-free survival''' (MFS) or '''distant metastasis–free survival''' (DMFS) (the period until [[metastasis]] is detected). Progression can be categorized as local progression, regional progression, locoregional progression, and metastatic progression.

==See also==
* [[Progression-free survival]]
* [[Response Evaluation Criteria in Solid Tumors]] (RECIST)
* [[Surveillance, Epidemiology, and End Results database]] (SEER)

==References==
((reflist))

[[Category:Demographics indicators]]
[[Category:Statistical ratios]]
[[Category:Epidemiology]]
[[Category:Survival]]

Pages transcluded onto the current version of this page (help):

Survival rate (edit)
Template:Ambox (view source) (template editor protected)
Template:Category handler (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Cite web (view source) (protected)
Template:Disputed (view source) (template editor protected)
Template:Expert needed (view source) (template editor protected)
Template:Expert needed/catcheck (view source) (template editor protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Main (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:Multiple issues (view source) (template editor protected)
Template:Multiple issues/styles.css (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:Resolve category redirect (view source) (template editor protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Trim (view source) (protected)
Category:Medicine articles needing expert attention (edit)
Module:Arguments (view source) (protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Disambiguation/templates (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Format link (view source) (template editor protected)
Module:Hatnote (view source) (template editor protected)
Module:Hatnote/styles.css (view source) (template editor protected)
Module:Hatnote list (view source) (template editor protected)
Module:Labelled list hatnote (view source) (template editor protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:Resolve category redirect (view source) (template editor protected)
Module:SDcat (view source) (protected)
Module:String (view source) (protected)
Module:Template redirect regex (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to Survival rate.

Retrieved from "https://en.wikipedia.org/wiki/Survival_rate"